Tumor Markers and Tumor-Volume–Related Determinants in Serum Before Treatment with 177Lu-Octreotate and at Time of Best Response in Patients with Elevated Values at Baseline
| Parameter | Reference value | Baseline | Best response | P |
| Chromogranin A (μg/L) | <95 | 979 | 514 | 0.002* |
| 5-HIAA (μmol/L) | <50 | 746 ± 166 | 437 ± 126 | 0.02* |
| Alkaline phosphatase (U/L) | <120 | 185 | 130 | 0.08 |
| Bone-specific alkaline phosphatase (μg/L) | <20.1 (men), <14.3 (premenopausal women), <22.4 (postmenopausal women) | 35 ± 10 | 29 ± 6 | 0.43 |
| Bilirubin (μmol/L) | <17 | 32 ± 6 | 16 ± 1 | 0.05 |
| γ-glutamyl transpeptidase (U/L) | <35 | 220 | 123 | 0.05 |
| Aspartate aminotransferase (U/L) | <31 | 79 ± 23 | 70 ± 12 | 0.63 |
| Alanine aminotransferase (U/L) | <31 | 76 ± 21 | 63 ± 16 | 0.38 |
| Lactate dehydrogenase (U/L) | <450 | 593 ± 108 | 419 ± 26 | 0.28 |
↵* Significant difference (Wilcoxon signed ranks test for chromogranin A and paired t test for 5-HIAA).
Data are mean ± SEM or median.